Organon Launches Publically Accessible Website on Its Clinical Trials
Today Organon announces the launch of a clinical trial website - www.organon-trials.com - that will provide results of the company’s completed trials and a registry of ongoing trials.
June 16, 2005, Oss, The Netherlands - Today Organon announces the launch of a clinical trial website - www.organon-trials.com - that will provide results of the company's completed trials and a registry of ongoing trials. The website will further increase the transparency of the clinical trials Organon sponsors. The site is freely accessible without restriction.
"Organon is committed to provide transparency about the trials we conduct by making this information available in the public domain. We are pleased to be one of the first pharmaceutical companies to introduce such an initiative," commented Dr Henk Jan Out, Head of Global Clinical Development at Organon. With this action, Organon follows the recommendation from the joint pharmaceutical company associations and editors of the major medical journals.
The clinical trial registry contains information on all phase III and beyond trials currently taking place.1 This includes a unique identifying number, purpose of the study, study type and design, eligibility criteria, target number of patients, countries where the study is running and contact information.
The clinical trial results section will summarize the findings of the clinical trials that have been performed with currently available major products of Organon. The number will grow as additional older trials are added. In addition, once trials posted on the registry have been completed and marketing approval gained in one country, the results from all studies - including those preceding the phase III trials - will be posted in the clinical trial results section. Similarly, Organon will also report results of earlier trials when already marketed drugs have been approved in new indications.
Both the registry and results sections provide scientific, non-promotional and comprehensive summaries of clinical trials in a consistent format irrespective of whether the results may be viewed as positive or negative for the medicine concerned. The site will be updated regularly to ensure the information is accurate and up-to-date.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
